Merck: positive phase III data for lung cancer drug
(CercleFinance.com) - Merck announces that the KEYNOTE-671 phase III trial of its Keytruda product has met the dual primary endpoint of overall survival (OS) in resectable stage II, IIIA or IIIB non-small cell lung cancer (NSCLC).
In a predefined interim analysis, Keytruda demonstrated a clinically and statistically significant improvement in OS as neoadjuvant and adjuvant treatment compared with preoperative chemotherapy for NSCLC.
Merck says that the full results of this analysis of KEYNOTE-671 will be presented at the 2023 European Society for Medical Oncology (ESMO) congress and shared with regulatory authorities worldwide.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
In a predefined interim analysis, Keytruda demonstrated a clinically and statistically significant improvement in OS as neoadjuvant and adjuvant treatment compared with preoperative chemotherapy for NSCLC.
Merck says that the full results of this analysis of KEYNOTE-671 will be presented at the 2023 European Society for Medical Oncology (ESMO) congress and shared with regulatory authorities worldwide.
Copyright (c) 2023 CercleFinance.com. All rights reserved.